Early Acute Graft Rejection in a Heart Transplanted Child with Dilated Cardiomyopathy

2020 ◽  
Vol 6 (2) ◽  
pp. 43-47
Author(s):  
Iolanda Muntean ◽  
Asmaa Carla Barmou ◽  
Anca Ileana Sin ◽  
Horatiu Suciu ◽  
Rodica Togănel
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Endomyocardial Biopsy ◽  
Allograft Rejection ◽  
Neonatal Period ◽  
Common Type ◽  
Acute Graft Rejection ◽  
End Stage Heart Failure ◽  
End Stage

AbstractDilated cardiomyopathy (DCM) is the most common type of cardiomyopathy in children. Heart transplantation is considered standard therapy in dilated cardiomyopathy with end-stage heart failure. We present a case of a 15-year-old patient diagnosed with DCM in the neonatal period, who underwent heart transplantation for end-stage heart failure. Despite the use of induction therapy, the endomyocardial biopsy performed at two weeks post-transplant revealed mixed moderate cellular (2R) and humoral (pAMR2) allograft rejection. Aggressive rejection treatment was initiated with good outcome. Besides endomyocardial biopsy, advanced echocardiography can also be a valuable noninvasive tool for rejection assessment.

170 Heart Transplantation in 11 Patients with End Stage Heart Failure Caused by Muscular Dystrophy

2012 ◽  
Vol 31 (4) ◽  
pp. S66
Author(s):  
U. Fuchs ◽  
U. Schulz ◽  
B. Schulze ◽  
A. Zittermann ◽  
K. Hakim-Meibodi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Muscular Dystrophy ◽  
Heart Transplantation ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Continuous Intravenous Infusion of Oxycodone for Dyspnea from End Stage-heart Failure due to Dilated Cardiomyopathy

2016 ◽  
Vol 11 (2) ◽  
pp. 529-533 ◽  
Author(s):  
Koji Ishii ◽  
Kumi Matsuo ◽  
Maki Ohno ◽  
Shigenori Muto ◽  
Satoru Morishita ◽  
...  
Keyword(s):  
Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Intravenous Infusion ◽  
Continuous Intravenous Infusion ◽  
End Stage Heart Failure ◽  
End Stage

Deloading of the Left Ventricle by Ventricular Assist Device Normalizes Increased Expression of Endothelin ET A Receptors But Not Endothelin-Converting Enzyme-1 in Patients With End-Stage Heart Failure

Circulation ◽  
2000 ◽  
Vol 102 (suppl_3) ◽  
Author(s):  
Henning Morawietz ◽  
Marten Szibor ◽  
Winfried Goettsch ◽  
Babett Bartling ◽  
Matthias Barton ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Ace Inhibitor ◽  
Ventricular Myocardium ◽  
Left Ventricular ◽  
Left Ventricular Myocardium ◽  
Converting Enzyme ◽  
Ventricular Assist ◽  
End Stage Heart Failure ◽  
End Stage

Background —Ventricular assist devices (VAD) are implanted in patients with end-stage heart failure for bridging the time until heart transplantation, resulting in hemodynamic unloading of the failing heart, improved cardiac contractile and mitochondrial function, and reversal of cardiac hypertrophy. It is unknown whether VAD unloading may affect the cardiac endothelin (ET) system, which has been proposed as one of the putative pathomechanisms of heart failure. Methods and Results —With the use of standard-calibrated, competitive reverse-transcription–polymerase chain reaction mRNA expression of components of the ET system was analyzed in left ventricular myocardium from nonfailing donor hearts, from failing hearts without and with ACE inhibitor therapy, and from patients with end-stage heart failure at the time of VAD implantation and 103±15 days after VAD implantation during removal with subsequent heart transplantation. ET receptor A (ET A ) was markedly upregulated in failing human myocardium. This increased ET A expression was not affected by ACE inhibitor treatment but was normalized by VAD unloading. ET A expression before or after VAD implantation did not correlate with duration of VAD implantation or suppression of Pro-ANP mRNA. ET B mRNA expression was unaffected by heart failure or VAD. In contrast, increased ET-converting enzyme-1 mRNA and ET-1 peptide levels in failing myocardium were partially normalized by ACE inhibition but not by VAD unloading. Conclusions —We conclude that VAD implantation normalizes ET A expression in failing human left ventricular myocardium, probably as the result of the beneficial effects of VAD unloading.

Heart Transplantation for End-Stage Heart Failure Due to Cardiac Sarcoidosis

2013 ◽  
Vol 45 (6) ◽  
pp. 2384-2386 ◽  
Author(s):  
D. Perkel ◽  
L.S.C. Czer ◽  
R.P. Morrissey ◽  
A. Ruzza ◽  
M. Rafiei ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Cardiac Sarcoidosis ◽  
End Stage Heart Failure ◽  
End Stage

Blood dendritic cell levels and phenotypic characteristics in relation to etiology of end-stage heart failure: Implications for dilated cardiomyopathy

2009 ◽  
Vol 131 (2) ◽  
pp. 246-256 ◽  
Author(s):  
Petros Athanassopoulos ◽  
Aggie H.M.M. Balk ◽  
Leonard M.B. Vaessen ◽  
Kadir Caliskan ◽  
Johanna J.M. Takkenberg ◽  
...  
Keyword(s):  
Heart Failure ◽  
Dendritic Cell ◽  
Dilated Cardiomyopathy ◽  
Phenotypic Characteristics ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Blood Dendritic Cell

scholarly journals Medium term results following heart transplantation for end stage heart failure: A single center experience of 257 patients

2020 ◽  
Vol 72 (6) ◽  
pp. 524-534
Author(s):  
K.R. Balakrishnan ◽  
K.G. Sureshrao ◽  
R. Ravikumar ◽  
T. Muralikrishna ◽  
K. Ganapathy Subramaniam ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Single Center ◽  
Medium Term ◽  
Single Center Experience ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Catheter ablation for atrial fibrillation in patients with end‐stage heart failure and eligibility for heart transplantation

2020 ◽  
Author(s):  
Christian Sohns ◽  
Nassir F. Marrouche ◽  
Angelika Costard‐Jäckle ◽  
Samuel Sossalla ◽  
Leonard Bergau ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Heart Transplantation ◽  
End Stage Heart Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document